The years 2008 and 2009 have posed considerable challenges for branded OTC marketers caused by global recession, price-conscious consumers, and strong competition from private labels. However, Rx-to-OTC switch remains a strong prospect for future growth of the industry.Continue reading
An FDA advisory committee is weighing in on the safety of OTC acetaminophen, the key active ingredient found in many OTC pain relievers, sleeping aids, and cough and cold medications. The proposed regulations suggest either cutting down dosages of acetaminophen or completely pulling combination drugs that contain acetaminophen off the shelves.Continue reading
Omega-3 represents one of the fastest growing segments in the food ingredients industry, both in the finished food product area and supplement industry. As marketing and promotion drives consumer sales, the ingredient suppliers are also doing there bit to maintain the dynamism of this sector, continuing to shape the finished product industry. Continue reading
The natural personal care market in the U.S. jumped 19% to $2 billion in sales for 2008, Kline’s Natural Personal Care 2008 study revealed earlier this year. Major marketers are in an excellent position to leverage the naturals proposition that began with the smaller niche players. Manufacturing economies of scale, a stronger position for negotiating supplier agreements, and well-developed distribution channels will allow brands like Unilever’s Dove and Colgate-Palmolive’s Softsoap to ride the naturals wave even during lean times.Continue reading
Sales for the Mucinex line of OTC cold medications were $137 mn in 2007 and grew 35.0% to reach $185 mn in 2008. Miralax is a novel Rx-to-OTC switch brand in the laxatives category and it grew from $40 mn in 2007, up 187.5% to $115 mn in 2008. Both brands are supported with strong advertising budgets and offer truly unique treatment of colds and constipation than private-label products in their respective categories. Continue reading
Private-label OTC medicines were up 8.2% over the same time period, within which antacids and allergy medicines posted the highest growth last year, driven primarily by increases in sales of private-label omeprazole (Procter & Gambles Prilosec OTC) and cetirizine (Johnson & Johnsons Zyrtec).
The following two areas distinctively posted very high growth mainly as a result of Rx-to-OTC switches: allergy, asthma, and sinus medications were up 17.3% as a result of strong sales from Johnson & Johnson’s Zyrtec brand, as well as its equivalent private-label cetirizine; feminine products was the other area that grew 7.3% in 2008 as a result of strong sales growth of personal lubricants, as well as the Rx-to-OTC switch brand Plan B by Barr Laboratories.